Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.68 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.68 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711243 | 0.86 | — | — | |
| SCHEMBL5761715 | 0.86 | — | — | |
| SCHEMBL1070277 | 0.86 | GNAI3 (0.81) | GNAI3GNAO1GNAI1KCNH2SOS1 | |
| SCHEMBL4979028 | 0.86 | — | — | |
| SCHEMBL3265058 | 0.85 | GNAI3 (0.92) | GNAI3GNAO1GNAI1KCNH2SOS1 | |
| Pyrimidine SCHEMBL8031985 | 0.84 | GNAI3 (0.51) | GNAI3GNAO1GNAI1KCNH2SOS1 | |
| SCHEMBL28793539 | 0.83 | GNAI3 (0.96) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL19604164 | 0.83 | GNAI3 (0.96) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL30092298 | 0.83 | GNAI3 (0.96) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL7319928 | 0.83 | GNAI3 (0.96) | GNAI3GNAO1GNAI1KCNH2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528937-B | Compound with selective inhibition effect on JAK2, application and medicine thereof | 四川大学华西医院 | 2025-04-04 | — | — | CN | disclosed |
| CN-119528937-A | Compound with selective inhibition effect on JAK2, application and medicine thereof | 四川大学华西医院 | 2025-02-28 | — | — | CN | disclosed |
| CN-116444504-A | 1- ((piperidin-4-yl) amino) propan-2-ol compound, preparation and application thereof | 中国农业大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020160707-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-08-13 | — | — | WO | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-1732917-B1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1968976-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-17 | — | — | EP | disclosed |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7291632-B2 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | ELLI LILLY AND COMPANY (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1663971-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | Eli Lilly and Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005035499-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287363-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists | HTR1F, HTR1A, HTR3B | GNAI3 803/4885GNAO1 811/4885GNAI1 768/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GNAI3 3162/4885GNAO1 3206/4885GNAI1 3170/4885 |
| US-20070270466-A1 | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists | HTR1F, HTR1A, HTR3B | GNAI3 1046/4885GNAO1 897/4885GNAI1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.